At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

The U.S. Centers for Disease Control and Prevention's vaccine experts are expected to vote on expanding access to respiratory ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

CDC panel expands RSV vaccine recommendations for at-risk adults aged 50-59, including Pfizer's Abrysvo. Read more here.

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices ...

Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, and adults 18 and older at increased risk of lower respiratory tract disease caused by RSV (RSV ...